HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Chronic Lymphocytic Leukemia Research
Lymphoma Diagnosis and Treatment
Acute Lymphoblastic Leukemia research
Publication details
- Journal / source
- Journal of the National Comprehensive Cancer Network
- Volume
- 24
- Issue
- 3.5
- Publication date
- 27 March 2026
- Language
- EN